{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:16:51Z","timestamp":1780568211761,"version":"3.54.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"DOI":"10.7759\/cureus.42870","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T03:17:41Z","timestamp":1691032661000},"source":"Crossref","is-referenced-by-count":8,"title":["Oral Therapeutics Post Menopausal Osteoporosis"],"prefix":"10.7759","author":[{"given":"Ryan  J","family":"Schroeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Staszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collyn","family":"O'Quin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Kallurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: us preventive services task force recommendation statement","volume":"319","author":"Curry SJ","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, et al.. Screening for osteoporosis to prevent fractures: us preventive services task force recommendation statement. JAMA. 2018, 319:2521-31. 10.1001\/jama.2018.7498","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005665","article-title":"Exercise for osteoporosis: a literature review of pathology and mechanism","volume":"13","author":"Zhang L","year":"2022","unstructured":"Zhang L, Zheng YL, Wang R, Wang XQ, Zhang H. Exercise for osteoporosis: a literature review of pathology and mechanism. Front Immunol. 2022, 13:1005665. 10.3389\/fimmu.2022.1005665","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff MS","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022, 33:2049-102. 10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho PM","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, et al.. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020, 26:1-46. 10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell R","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019, 104:1595-622. 10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback D","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. 2020, 105:10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.012","article-title":"Tissue-selectivity: the mechanism of action of tibolone","volume":"48 Suppl 1","author":"Kloosterboer HJ","year":"2004","unstructured":"Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004, 48 Suppl 1:S30-40. 10.1016\/j.maturitas.2004.02.012","journal-title":"Maturitas"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-7002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis","volume":"23","author":"Shea B","year":"2002","unstructured":"Shea B, Wells G, Cranney A, et al.. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002, 23:552-9. 10.1210\/er.2001-7002","journal-title":"Endocr Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.8.869","article-title":"Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women","volume":"166","author":"Prince RL","year":"2006","unstructured":"Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med. 2006, 166:869-75. 10.1001\/archinte.166.8.869","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4580","article-title":"Calcium intake and risk of fracture: systematic review","volume":"351","author":"Bolland MJ","year":"2015","unstructured":"Bolland MJ, Leung W, Tai V, Bastin S, Gamble GD, Grey A, Reid IR. Calcium intake and risk of fracture: systematic review. BMJ. 2015, 351:h4580. 10.1136\/bmj.h4580","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19344","article-title":"Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis","volume":"318","author":"Zhao JG","year":"2017","unstructured":"Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA. 2017, 318:2466-82. 10.1001\/jama.2017.19344","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50393","article-title":"Controversies in medicine: the role of calcium and vitamin D supplements in adults","volume":"211","author":"Reid IR","year":"2019","unstructured":"Reid IR, Bolland MJ. Controversies in medicine: the role of calcium and vitamin D supplements in adults. Med J Aust. 2019, 211:468-73. 10.5694\/mja2.50393","journal-title":"Med J Aust"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen S","year":"2007","unstructured":"Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007, 92:1415-23. 10.1210\/jc.2006-1404","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000227.pub2","article-title":"Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis","author":"Avenell A","year":"2005","unstructured":"Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005. CD000227. 10.1002\/14651858.CD000227.pub2"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30265-1","article-title":"Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis","volume":"6","author":"Bolland MJ","year":"2018","unstructured":"Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018, 6:847-58. 10.1016\/S2213-8587(18)30265-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3185","article-title":"Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman DC","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al.. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US Preventive Services Task Force recommendation statement. JAMA. 2018, 319:1592-9. 10.1001\/jama.2018.3185","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","unstructured":"Management of osteoporosis in postmenopausal women. the 2021 position statement of The North American Menopause Society. Menopause. 2021, 28:973-97. 10.1097\/GME.0000000000001831","journal-title":"Menopause"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.003350","article-title":"Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements","volume":"94","author":"Wallace RB","year":"2011","unstructured":"Wallace RB, Wactawski-Wende J, O'Sullivan MJ, Larson JC, Cochrane B, Gass M, Masaki K. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr. 2011, 94:270-7. 10.3945\/ajcn.110.003350","journal-title":"Am J Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2732-3","article-title":"Calcium supplement intake and risk of cardiovascular disease in women","volume":"25","author":"Paik JM","year":"2014","unstructured":"Paik JM, Curhan GC, Sun Q, Rexrode KM, Manson JE, Rimm EB, Taylor EN. Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int. 2014, 25:2047-56. 10.1007\/s00198-014-2732-3","journal-title":"Osteoporos Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis","volume":"341","author":"Bolland MJ","year":"2010","unstructured":"Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010, 341:c3691. 10.1136\/bmj.c3691","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-0694-y","article-title":"Effects of dairy products on bone mineral density in healthy postmenopausal women: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Shi Y","year":"2020","unstructured":"Shi Y, Zhan Y, Chen Y, Jiang Y. Effects of dairy products on bone mineral density in healthy postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2020, 15:48. 10.1007\/s11657-020-0694-y","journal-title":"Arch Osteoporos"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090513","article-title":"A 5-year cohort study of the effects of high protein intake on lean mass and BMC in elderly postmenopausal women","volume":"24","author":"Meng X","year":"2009","unstructured":"Meng X, Zhu K, Devine A, Kerr DA, Binns CW, Prince RL. A 5-year cohort study of the effects of high protein intake on lean mass and BMC in elderly postmenopausal women. J Bone Miner Res. 2009, 24:1827-34. 10.1359\/jbmr.090513","journal-title":"J Bone Miner Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/69.1.147","article-title":"Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women","volume":"69","author":"Munger RG","year":"1999","unstructured":"Munger RG, Cerhan JR, Chiu BC. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr. 1999, 69:147-52. 10.1093\/ajcn\/69.1.147","journal-title":"Am J Clin Nutr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/1389450121666201027124947","article-title":"Post-menopausal osteoporosis and probiotics","volume":"22","author":"Huidrom S","year":"2021","unstructured":"Huidrom S, Beg MA, Masood T. Post-menopausal osteoporosis and probiotics. Curr Drug Targets. 2021, 22:816-22. 10.2174\/1389450121666201027124947","journal-title":"Curr Drug Targets"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000100","article-title":"Effects of walking on the preservation of bone mineral density in perimenopausal and postmenopausal women: a systematic review and meta-analysis","volume":"20","author":"Ma D","year":"2013","unstructured":"Ma D, Wu L, He Z. Effects of walking on the preservation of bone mineral density in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Menopause. 2013, 20:1216-26. 10.1097\/GME.0000000000000100","journal-title":"Menopause"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2016-096547","article-title":"Exercise to prevent falls in older adults: an updated systematic review and meta-analysis","volume":"51","author":"Sherrington C","year":"2017","unstructured":"Sherrington C, Michaleff ZA, Fairhall N, et al.. Exercise to prevent falls in older adults: an updated systematic review and meta-analysis. Br J Sports Med. 2017, 51:1750-8. 10.1136\/bjsports-2016-096547","journal-title":"Br J Sports Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6210201","article-title":"Swimming as treatment for osteoporosis: a systematic review and meta-analysis","volume":"2020","author":"Su Y","year":"2020","unstructured":"Su Y, Chen Z, Xie W. Swimming as treatment for osteoporosis: a systematic review and meta-analysis. Biomed Res Int. 2020, 2020:6210201. 10.1155\/2020\/6210201","journal-title":"Biomed Res Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3097","article-title":"Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman DC","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al.. Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force recommendation statement. JAMA. 2018, 319:1696-704. 10.1001\/jama.2018.3097","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell RG","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008, 19:733-59. 10.1007\/s00198-007-0540-8","journal-title":"Osteoporos Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.593511","article-title":"Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010)","volume":"21","author":"Sun S","year":"2011","unstructured":"Sun S, McKenna CE. Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). Expert Opin Ther Pat. 2011, 21:1433-51. 10.1517\/13543776.2011.593511","journal-title":"Expert Opin Ther Pat"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial.","volume":"85","author":"Black DM","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, et al.. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. . J Clin Endocrinol Metab. 2000, 85:4118-24. 10.1210\/jcem.85.11.6953","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris ST","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999, 282:1344-52. 10.1001\/jama.282.14.1344","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster J","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al.. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000, 11:83-91. 10.1007\/s001980050010","journal-title":"Osteoporos Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut CH 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C, et al.. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004, 19:1241-9. 10.1359\/JBMR.040325","journal-title":"J Bone Miner Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.573976","article-title":"Oral treatment with bisphosphonates of osteoporosis does not increase the risk of severe gastrointestinal side effects: a meta-analysis of randomized controlled trials","volume":"11","author":"D\u00f6m\u00f6t\u00f6r ZR","year":"2020","unstructured":"D\u00f6m\u00f6t\u00f6r ZR, V\u00f6rhendi N, Han\u00e1k L, et al.. Oral treatment with bisphosphonates of osteoporosis does not increase the risk of severe gastrointestinal side effects: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2020, 11:573976. 10.3389\/fendo.2020.573976","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial","volume":"160","author":"Bauer DC","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K, et al.. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000, 160:517-25. 10.1001\/archinte.160.4.517","journal-title":"Arch Intern Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4065\/77.10.1044","article-title":"Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study","volume":"77","author":"Greenspan S","year":"2002","unstructured":"Greenspan S, Field-Munves E, Tonino R, et al.. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002, 77:1044-52. 10.4065\/77.10.1044","journal-title":"Mayo Clin Proc"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003548","article-title":"Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study","volume":"20","author":"Eisman JA","year":"2004","unstructured":"Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2004, 20:699-705. 10.1185\/030079904125003548","journal-title":"Curr Med Res Opin"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou PD","year":"2009","unstructured":"Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009, 8:96-110. 10.14310\/horm.2002.1226","journal-title":"Hormones (Athens)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo P","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, et al.. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019, 104:1623-30. 10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-009-9323-x","article-title":"Gastric and esophagus events before and during treatment of osteoporosis","volume":"86","author":"Vestergaard P","year":"2010","unstructured":"Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int. 2010, 86:110-5. 10.1007\/s00223-009-9323-x","journal-title":"Calcif Tissue Int"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-022-02272-z","article-title":"Novel formulations of oral bisphosphonates in the treatment of osteoporosis","volume":"34","author":"Fuggle N","year":"2022","unstructured":"Fuggle N, Al-Daghri N, Bock O, et al.. Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res. 2022, 34:2625-34. 10.1007\/s40520-022-02272-z","journal-title":"Aging Clin Exp Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000501","article-title":"Rare adverse effects of bisphosphonate therapy","volume":"26","author":"Ilyas Z","year":"2019","unstructured":"Ilyas Z, Camacho PM. Rare adverse effects of bisphosphonate therapy. Curr Opin Endocrinol Diabetes Obes. 2019, 26:335-8. 10.1097\/MED.0000000000000501","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer DC","year":"2018","unstructured":"Bauer DC, Black DM, Bouxsein ML, et al.. Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression. J Bone Miner Res. 2018, 33:634-42. 10.1002\/jbmr.3355","journal-title":"J Bone Miner Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black DM","year":"2019","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019, 40:333-68. 10.1210\/er.2018-00001","journal-title":"Endocr Rev"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler RA","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, et al.. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016, 31:16-35. 10.1002\/jbmr.2708","journal-title":"J Bone Miner Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo JC","year":"2010","unstructured":"Lo JC, O'Ryan FS, Gordon NP, et al.. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010, 68:243-53. 10.1016\/j.joms.2009.03.050","journal-title":"J Oral Maxillofac Surg"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black DM","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, et al.. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006, 296:2927-38. 10.1001\/jama.296.24.2927","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher J","year":"2015","unstructured":"Schilcher J, Koeppen V, Aspenberg P, Micha\u00eblsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015, 86:100-7. 10.3109\/17453674.2015.1004149","journal-title":"Acta Orthop"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams AL","year":"2018","unstructured":"Adams AL, Adams JL, Raebel MA, et al.. Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Miner Res. 2018, 33:1252-9. 10.1002\/jbmr.3420","journal-title":"J Bone Miner Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.11.011","article-title":"The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis","volume":"53","author":"Nelson ER","year":"2013","unstructured":"Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone. 2013, 53:42-50. 10.1016\/j.bone.2012.11.011","journal-title":"Bone"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.4.8","article-title":"International Union of Pharmacology. LXIV. Estrogen receptors","volume":"58","author":"Dahlman-Wright K","year":"2006","unstructured":"Dahlman-Wright K, Cavailles V, Fuqua SA, et al.. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006, 58:773-81. 10.1124\/pr.58.4.8","journal-title":"Pharmacol Rev"},{"key":"ref53","article-title":"Raloxifene","author":"Quintanilla Rodriguez BS","year":"2022","unstructured":"Quintanilla Rodriguez BS, Correa R. Raloxifene. Quintanilla Rodriguez BS, Correa R (ed): StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes N","year":"2019","unstructured":"Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019, 116:135-70. 10.1016\/bs.apcsb.2019.01.001","journal-title":"Adv Protein Chem Struct Biol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation","volume":"949","author":"Komm BS","year":"2001","unstructured":"Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001, 949:317-26. 10.1111\/j.1749-6632.2001.tb04039.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.4184\/asj.2016.10.4.787","article-title":"Selective estrogen receptor modulators","volume":"10","author":"An KC","year":"2016","unstructured":"An KC. Selective estrogen receptor modulators. Asian Spine J. 2016, 10:787-91. 10.4184\/asj.2016.10.4.787","journal-title":"Asian Spine J"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4158\/EP.7.2.113","article-title":"Selective estrogen receptor modulators: from bench to bedside and back","volume":"7","author":"Whitaker MD","year":"2001","unstructured":"Whitaker MD. Selective estrogen receptor modulators: from bench to bedside and back. Endocr Pract. 2001, 7:113-9. 10.4158\/EP.7.2.113","journal-title":"Endocr Pract"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.782002","article-title":"The use of raloxifene in osteoporosis treatment","volume":"14","author":"D'Amelio P","year":"2013","unstructured":"D'Amelio P, Isaia GC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother. 2013, 14:949-56. 10.1517\/14656566.2013.782002","journal-title":"Expert Opin Pharmacother"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2007.0097","article-title":"Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis","volume":"18","author":"Ozmen B","year":"2007","unstructured":"Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw. 2007, 18:148-53. 10.1684\/ecn.2007.0097","journal-title":"Eur Cytokine Netw"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-012-1288-9","article-title":"The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor \u03b2 expression","volume":"366","author":"Tu Z","year":"2012","unstructured":"Tu Z, Li H, Ma Y, et al.. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor \u03b2 expression. Mol Cell Biochem. 2012, 366:111-22. 10.1007\/s11010-012-1288-9","journal-title":"Mol Cell Biochem"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100454108","article-title":"Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone","volume":"108","author":"B\u00f6rjesson AE","year":"2011","unstructured":"B\u00f6rjesson AE, Windahl SH, Lagerquist MK, et al.. Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci U S A. 2011, 108:6288-93. 10.1073\/pnas.1100454108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-012-2404-y","article-title":"Recommendations for raloxifene use in daily clinical practice in the Swiss setting","volume":"21","author":"Lippuner K","year":"2012","unstructured":"Lippuner K, Buchard PA, De Geyter C, et al.. Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Eur Spine J. 2012, 21:2407-17. 10.1007\/s00586-012-2404-y","journal-title":"Eur Spine J"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas PD","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, et al.. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002, 87:3609-17. 10.1210\/jcem.87.8.8750","journal-title":"J Clin Endocrinol Metab"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings SR","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, et al.. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281:2189-97. 10.1001\/jama.281.23.2189","journal-title":"JAMA"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2174\/1874325000903010014","article-title":"Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice","volume":"3","author":"Rey JR","year":"2009","unstructured":"Rey JR, Cervino EV, Rentero ML, Crespo EC, Alvaro AO, Casillas M. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J. 2009, 3:14-21. 10.2174\/1874325000903010014","journal-title":"Open Orthop J"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino S","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, et al.. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004, 96:1751-61. 10.1093\/jnci\/djh319","journal-title":"J Natl Cancer Inst"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting","volume":"21","author":"Martino S","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005, 21:1441-52. 10.1185\/030079905X61839","journal-title":"Curr Med Res Opin"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor E","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al.. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006, 355:125-37. 10.1056\/NEJMoa062462","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.01.033","article-title":"Raloxifene and risk for stroke based on the framingham stroke risk score","volume":"122","author":"Barrett-Connor E","year":"2009","unstructured":"Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med. 2009, 122:754-61. 10.1016\/j.amjmed.2009.01.033","journal-title":"Am J Med"},{"key":"ref70","article-title":"Bazedoxifene","author":"Raina PM","year":"2022","unstructured":"Raina PM, Parmar M. Bazedoxifene. Raina PM, Parmar M (ed): StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4903-273","article-title":"Conjugated estrogens and bazedoxifene","volume":"49","author":"Cada DJ","year":"2014","unstructured":"Cada DJ, Baker DE. Conjugated estrogens and bazedoxifene. Hosp Pharm. 2014, 49:273-83. 10.1310\/hpj4903-273","journal-title":"Hosp Pharm"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11422602","article-title":"Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis","volume":"4","author":"Komm BS","year":"2012","unstructured":"Komm BS, Chines AA. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2012, 4:21-34. 10.1177\/1759720X11422602","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller PD","year":"2008","unstructured":"Miller PD, Chines AA, Christiansen C, et al.. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008, 23:525-35. 10.1359\/jbmr.071206","journal-title":"J Bone Miner Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman SL","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, et al.. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008, 23:1923-34. 10.1359\/jbmr.080710","journal-title":"J Bone Miner Res"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1615882","article-title":"Bazedoxifene for the treatment of osteoporosis","volume":"20","author":"Yavropoulou MP","year":"2019","unstructured":"Yavropoulou MP, Makras P, Anastasilakis AD. Bazedoxifene for the treatment of osteoporosis. Expert Opin Pharmacother. 2019, 20:1201-10. 10.1080\/14656566.2019.1615882","journal-title":"Expert Opin Pharmacother"},{"key":"ref76","unstructured":"Bazedoxifene. (2023). Accessed. February 25, 2023: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/154257.."},{"key":"ref77","article-title":"Conjugated estrogens\/bazedoxifene (duavee): a novel agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis","volume":"40","author":"Goldberg T","year":"2015","unstructured":"Goldberg T, Fidler B. Conjugated estrogens\/bazedoxifene (duavee): a novel agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. P T. 2015, 40:178-82.","journal-title":"P T"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson JE","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML, et al.. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013, 310:1353-68. 10.1001\/jama.2013.278040","journal-title":"JAMA"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4414-z","article-title":"Estrogen therapy for osteoporosis in the modern era","volume":"29","author":"Levin VA","year":"2018","unstructured":"Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018, 29:1049-55. 10.1007\/s00198-018-4414-z","journal-title":"Osteoporos Int"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0856","article-title":"Update on estrogens and the skeleton","volume":"95","author":"Khosla S","year":"2010","unstructured":"Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab. 2010, 95:3569-77. 10.1210\/jc.2010-0856","journal-title":"J Clin Endocrinol Metab"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-1-199501010-00002","article-title":"Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group","volume":"122","author":"Cauley JA","year":"1995","unstructured":"Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995, 122:9-16. 10.7326\/0003-4819-122-1-199501010-00002","journal-title":"Ann Intern Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw JE","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288:321-33. 10.1001\/jama.288.3.321","journal-title":"JAMA"},{"key":"ref83","article-title":"Postmenopausal tibolone therapy: biologic principles and applied clinical practice","volume":"9","author":"Notelovitz M","year":"2007","unstructured":"Notelovitz M. Postmenopausal tibolone therapy: biologic principles and applied clinical practice. MedGenMed. 2007, 9:2.","journal-title":"MedGenMed"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(01)00044-9","article-title":"Tibolone: a steroid with a tissue-specific mode of action","volume":"76","author":"Kloosterboer HJ","year":"2001","unstructured":"Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001, 76:231-8. 10.1016\/S0960-0760(01)00044-9","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2018.09.005","article-title":"Postmenopausal osteoporosis: assessment and management","volume":"32","author":"Rizzoli R","year":"2018","unstructured":"Rizzoli R. Postmenopausal osteoporosis: assessment and management. Best Pract Res Clin Endocrinol Metab. 2018, 32:739-57. 10.1016\/j.beem.2018.09.005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/biology10030211","article-title":"Effect of tibolone on bone mineral density in postmenopausal women: systematic review and meta-analysis","volume":"10","author":"Castrej\u00f3n-Delgado L","year":"2021","unstructured":"Castrej\u00f3n-Delgado L, Castel\u00e1n-Mart\u00ednez OD, Clark P, Gardu\u00f1o-Espinosa J, Mendoza-N\u00fa\u00f1ez VM, S\u00e1nchez-Rodr\u00edguez MA. Effect of tibolone on bone mineral density in postmenopausal women: systematic review and meta-analysis. Biology (Basel). 2021, 10:10.3390\/biology10030211","journal-title":"Biology (Basel)"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(99)00032-8","article-title":"Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis","volume":"32","author":"Fedele L","year":"1999","unstructured":"Fedele L, Bianchi S, Raffaelli R, et al.. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas. 1999, 32:189-93. 10.1016\/S0378-5122(99)00032-8","journal-title":"Maturitas"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmx011","article-title":"The management of menopause in women with a history of endometriosis: a systematic review","volume":"23","author":"Gemmell LC","year":"2017","unstructured":"Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017, 23:481-500. 10.1093\/humupd\/dmx011","journal-title":"Hum Reprod Update"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s1043","article-title":"Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence","volume":"3","author":"Garefalakis M","year":"2008","unstructured":"Garefalakis M, Hickey M. Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. Clin Interv Aging. 2008, 3:1-8. 10.2147\/cia.s1043","journal-title":"Clin Interv Aging"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008536.pub3","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso G","year":"2016","unstructured":"Formoso G, Perrone E, Maltoni S, et al.. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016, 10:CD008536. 10.1002\/14651858.CD008536.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3097","article-title":"Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy","volume":"14","author":"Bundred NJ","year":"2012","unstructured":"Bundred NJ, Kenemans P, Yip CH, et al.. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res. 2012, 14:R13. 10.1186\/bcr3097","journal-title":"Breast Cancer Res"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings SR","year":"2008","unstructured":"Cummings SR, Ettinger B, Delmas PD, et al.. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008, 359:697-708. 10.1056\/NEJMoa0800743","journal-title":"N Engl J Med"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00007.x","article-title":"Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator","volume":"25","author":"Campisi R","year":"2007","unstructured":"Campisi R, Marengo FD. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator. Cardiovasc Drug Rev. 2007, 25:132-45. 10.1111\/j.1527-3466.2007.00007.x","journal-title":"Cardiovasc Drug Rev"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.014","article-title":"Tibolone: how does its mechanism of action translate into clinical effects","volume":"48 Suppl 1","author":"Kenemans P","year":"2004","unstructured":"Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas. 2004, 48 Suppl 1:S1-3. 10.1016\/j.maturitas.2004.02.014","journal-title":"Maturitas"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/172707-oral-therapeutics-post-menopausal-osteoporosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:31Z","timestamp":1707509011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/172707-oral-therapeutics-post-menopausal-osteoporosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":94,"URL":"https:\/\/doi.org\/10.7759\/cureus.42870","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}